Effect of Galantamine on Inflammation and Cognition

Exclusion criteria

• . Current enrollment or plans to enroll in another smoking cessation program in the next 7 months.
• . Regular (daily) use of electronic cigarettes, chewing tobacco, snuff, snus, cigars, cigarillos, or pipes.
• . Current use or plans to use nicotine substitutes (gum, patch, lozenge, e-cigarette) or smoking cessation treatments in the next 7 months.
• . Current untreated and unstable diagnosis of substance abuse or dependence (if past use and if receiving treatment and stable for at least 30 days, eligible)
• . Positive urine drug screen for cocaine, methamphetamines, phencyclidine (PCP), barbiturates, ecstasy (MDMA), at Intake or Lab visits. Those who screen positive for amphetamines, benzodiazepines, methadone, oxycodone, and/or opiates (low level cut-off 300 ng/mL) and who are prescribed these medications will be reviewed on a case-by-case basis by the study physician and PIs (see Measures and Table 1 for details). Participants believed to have a false-positive result on the drug screen may continue in the study, with investigator approval.
• . Women who are pregnant, planning a pregnancy or lactating
• . Current diagnosis of unstable and untreated major depression (if stable for at least 30 days, eligible)
• . Current or past diagnosis of psychotic disorder